International name of the drug: eprosartan.
One tablet Teveten film coated contains 735 mg of active substance 8 eprosartanamezilata that compares 600 mg eprosartan.
As auxiliary substances are used: purified water, starch, pregelatinized, microcrystalline cellulose, crospovidone, lactose monohydrate, magnesium stearate. The shell is made of: Opadry white (OY-S-9603) with the dye - titanium dioxide (E171).
The pharmacological action of the drug Teveten
Angiotensin receptor blockers, hypotensive, vasodilating action.
It has a selective effect on angiotensin receptors in the kidney and the adrenal cortex. It forms a strong bond to the receptors, with subsequent slow dissociation. Eprosartan reduces or prevents the development of the effect of angiotensin II.
Reduces Arterial vasoconstriction of the pulmonary circulation pressure, total peripheral vascular resistance, secretion of aldosterone.
Prolonged use Teveten suppresses the proliferative action of angiotensin II on smooth muscle cells of the myocardium and blood vessels. The antihypertensive effect persists over 24 hours, excluding the development of orthostatic hypotension after the first dose. With regular use, after 2-3 weeks there comes the stabilization of the antihypertensive effect.
There was no impact on the level of eprosartan triglyceride levels in patients with hypertension. Teveten, taken on an empty stomach does not affect the blood glucose level is not reflected in the purine metabolism and does not significantly affect the excretion of uric acid. Discontinuation Teveten is not accompanied by signs of "withdrawal syndrome".
Bioavailability after single administration of 300 mg of 13%.
Eprosartan has a high protein binding of plasma - 98%, with the level being associated does not depend on age, gender or hepatic function of the patient. The level being associated does not change when not much expression, or an average level of kidney failure, but may be reduced when it is severe.
The maximum concentration of the drug in the blood is reached after 1-2 hours after administration. Ingestion absorption decreases by 25%. The half-life of 5-9 hours.
Write mainly with faeces about 90% and 7% in the urine. About 2% is excreted through the kidneys as glucuronide. Like its analogs Teveten hardly accumulates in the body. Sex, weight, race did not affect the pharmacokinetics Teveten. The pharmacokinetics of the drug in patients under 18 years has not been studied.
Teveten is indicated for hypertension.
Teveten is contraindicated
- if you are hypersensitive to the active substance or other components of the drug;
- pregnant women;
- patients under 18 years of age;
- intolerance to lactose or glucose-galaktoznoymalabsorbtsii syndrome.
Precautions taken at: severe chronic heart failure, bilateral renal artery stenosis, renal insufficiency (creatinine clearance less than 60 ml / min).
The drug Teveten during pregnancy and lactation
According to the instructions Teveten is not recommended to take during pregnancy. In determining the pregnancy the drug should be immediately discontinued. If there is a need for continued therapy is needed transition to Teveten equivalents or alternative antihypertensive drugs, the admissibility of which admission during pregnancy has been established. Admission Teveten on the 2nd and 3rd trimester of pregnancy has a toxic effect on the fetus - worsening renal function, leads to a delay of ossification of the skull bones. Newborns whose mothers took during pregnancy Teveten should be screened for the presence of hypotension.
Data on the penetration of the drug into the milk was obtained. If you need to conduct therapy Tevetenom, breastfeeding should be discontinued.
It is taken orally, regardless of the meal. The daily dosage recommended instructions Teveten is 1 tablet (735, 8 mg) single dose in the morning. The maximum daily dose of 1200 mg.
Practical reviews of Teveten treatment have shown that the elderly and persons with impaired hepatic function dose adjustment is required. For patients with renal insufficiency maximum allowed daily dose is 600 mg. Allowed continuous use of Teveten.
From recorded comments about Teveten treatment, side effects often manifest themselves in the form of:
- pronounced fall in blood pressure;
- allergic skin reactions;
- complaints about the state of the digestive system (nausea, diarrhea, vomiting);
- renal dysfunction.
About Teveten overdose obtained limited data. Symptoms of overdose may be expressed by lowering blood pressure. As the treatment of symptomatic therapy is recommended.
Teveten Interaction with other drugs
Teveten has no effect on the pharmacokinetics of warfarin, digoxin and of glibenclamide. In turn, on the pharmacokinetics of Teveten not affect fluconazole, ketoconazole and ranitidine.
The combination is allowed Teveten with thiazide diuretics and calcium channel blockers, while noting the mutual reinforcement of the hypotensive effect. Guide Teveten permits its use in conjunction with a lipid-lowering drug, including: pravastatin, lovastatin, gemfibrozil, simvastatin, fenofibrate.
As is the case with most of Teveten analogues, patients with a reduced volume of circulating blood before treatment with required correction BCC.
Patients with renal insufficiency, prior to appointment and during treatment, you need to monitor renal function. With the deterioration of renal activity doctor should review the need for continued treatment.
No comments were received that Teveten adversely affects the ability to drive. Due to possible dizziness recommended caution when driving and other potentially dangerous activities.
Storage conditions Teveten
The product is stored at room temperature, out of reach of children.
2 years. It is unacceptable to use the drug after the deadline.